Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
Peng Yuan, Binghe Xu National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Binghe XuNational Cancer Center, National Clinical Re...
Guardado en:
Autores principales: | Yuan P, Xu B |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/93ca463d3c6d472ea7ed8d651f94b2a4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
por: Puhalla S, et al.
Publicado: (2016) -
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
por: Elena I. Kovalenko, et al.
Publicado: (2020) -
Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types
por: Tamami Morisaki, et al.
Publicado: (2021) -
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
por: Irina V. Kolyadina, et al.
Publicado: (2020) -
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
por: Irina V. Kolyadina, et al.
Publicado: (2021)